Get access

Zizyphus jujuba and its Active Component Jujuboside B Inhibit Platelet Aggregation

Authors

  • Eun Ji Seo,

    1. Department of Physiology, Ajou University School of Medicine, Suwon, Republic of Korea
    2. Brain Korea 21 for Division of Cell Transformation and Restoration, Ajou University School of Medicine, Suwon, Republic of Korea
    Search for more papers by this author
  • So Young Lee,

    1. Natural Products Research Institute and College of Pharmacy, Seoul National University, Seoul, Republic of Korea
    Search for more papers by this author
  • Sam Sik Kang,

    1. Natural Products Research Institute and College of Pharmacy, Seoul National University, Seoul, Republic of Korea
    Search for more papers by this author
  • Yi-Sook Jung

    Corresponding author
    1. Brain Korea 21 for Molecular Science and Technology, Ajou University, Suwon, Republic of Korea
    2. Research Institute of Pharmaceutical Sciences and Technology, Ajou University, Suwon, Republic of Korea
    • College of Pharmacy, Ajou University, Suwon, Republic of Korea
    Search for more papers by this author

Correspondence to: Yi-Sook Jung, College of Pharmacy, Department of Molecular Science and Technology, Ajou University, Suwon 443–749, Republic of Korea.

E-mail: yisjung@ajou.ac.kr

Abstract

The seeds of Zizyphus jujuba (SZJ), a famous oriental traditional medicine, have been reported to exhibit diverse activities in biological systems including the cardiovascular system. However, little information is available on its antiplatelet activity. This study was undertaken to investigate the antiplatelet effects of the ethanolic extract of SZJ (ESZJ) and of its principal components jujuboside A and B. In the in vitro platelet aggregation study, ESZJ exhibited significant and concentration-dependent inhibitory effects on collagen-, thrombin-, and AA-induced platelet aggregation. In addition, ESZJ-treated mice showed significantly the prolongation of bleeding times and the protection against thromboembolic attack. A comparison of the effects of jujuboside A and B on platelet aggregation revealed that only jujuboside B had potent inhibitory effects on collagen-, thrombin-, AA-, and ADP-induced aggregation. Jujuboside B also exhibited superior protection on thromboembolic model. Furthermore, jujuboside B had a significant inhibitory effect on collagen-induced thromboxane A2 production in rat platelets. This study describes the antiplatelet effects of ESZJ and of its active component jujuboside B, and its findings suggest that these agents be considered as components of preventive and therapeutic herbal drugs targeting cardiovascular diseases associated with platelet hyperaggregation. Copyright © 2012 John Wiley & Sons, Ltd.

Get access to the full text of this article

Ancillary